[
    [
        {
            "time": "",
            "original_text": "复星医药跌5.89% 中信证券中泰证券刚喊买入",
            "features": {
                "keywords": [
                    "复星医药",
                    "中信证券",
                    "中泰证券",
                    "买入"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "复星医药跌5.89% 中信证券中泰证券刚喊买入",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "恒指缩量收跌1.08%，医药、科技股跌幅居前",
            "features": {
                "keywords": [
                    "恒指",
                    "医药",
                    "科技股",
                    "跌幅"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "恒指缩量收跌1.08%，医药、科技股跌幅居前",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "上海区域股周刊：21家机构调研思源电气 5亿融资买入复星医药",
            "features": {
                "keywords": [
                    "复星医药",
                    "机构调研",
                    "融资买入"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "上海区域股周刊：21家机构调研思源电气 5亿融资买入复星医药",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "港股医疗保健板块回调明显，复星医药跌逾8%",
            "features": {
                "keywords": [
                    "复星医药",
                    "医疗保健",
                    "回调"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "港股医疗保健板块回调明显，复星医药跌逾8%",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "复星医药跌8%，港股医疗板块又遭“血洗”？恒生医疗ETF（513060）持续溢价 交易价格异常",
            "features": {
                "keywords": [
                    "复星医药",
                    "港股医疗",
                    "血洗",
                    "恒生医疗ETF"
                ],
                "sentiment_score": -0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "复星医药跌8%，港股医疗板块又遭“血洗”？恒生医疗ETF（513060）持续溢价 交易价格异常",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 8,
                "Time_Proximity": 9,
                "Headline_Structure": 10,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "复星医药上半年营收同比增20.85%，创新产品落地促产品结构转型",
            "features": {
                "keywords": [
                    "复星医药",
                    "营收增长",
                    "创新产品",
                    "产品结构转型"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药上半年营收同比增20.85%，创新产品落地促产品结构转型",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "上证50跌幅扩大至1%，中国中免、复星医药跌超3%",
            "features": {
                "keywords": [
                    "上证50",
                    "中国中免",
                    "复星医药",
                    "跌幅"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "上证50跌幅扩大至1%，中国中免、复星医药跌超3%",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "FDA正式批准首个新冠疫苗 复星医药吴以芳：将积极沟通 争取早日将其推向国内市场",
            "features": {
                "keywords": [
                    "FDA",
                    "新冠疫苗",
                    "复星医药",
                    "吴以芳",
                    "国内市场"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "FDA正式批准首个新冠疫苗 复星医药吴以芳：将积极沟通 争取早日将其推向国内市场",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]